Edwards Lifesciences ROI - Return on Investment 2010-2024 | EW

Edwards Lifesciences return on investment for the quarter ending September 30, 2024 was 71.7.

  • Edwards Lifesciences average return on investment for 2023 was 20.97, a 9.96% increase from 2022.
  • Edwards Lifesciences average return on investment for 2022 was 23.29, a 4.24% decline from 2021.
  • Edwards Lifesciences average return on investment for 2021 was 24.32, a 27.87% decline from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

Edwards Lifesciences ROI - Return on Investment 2010-2024 | EW

  • Edwards Lifesciences average return on investment for 2023 was 20.97, a 9.96% increase from 2022.
  • Edwards Lifesciences average return on investment for 2022 was 23.29, a 4.24% decline from 2021.
  • Edwards Lifesciences average return on investment for 2021 was 24.32, a 27.87% decline from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$214.1B
Intuitive Surgical (ISRG)$183.6B
Alcon (ALC)$45.1B
IQVIA Holdings (IQV)$40.2B
IDEXX Laboratories (IDXX)$34.7B
DexCom (DXCM)$26.8B
Waters (WAT)$23B
STERIS (STE)$22.4B
SONOVA HOLDING (SONVY)$21.9B
Hologic (HOLX)$18.7B
Fresenius Medical Care AG KGaA (FMS)$12.4B
Sysmex ADR (SSMXY)$11.9B
Globus Medical (GMED)$11.2B
Teleflex (TFX)$9.4B
Penumbra (PEN)$9B
Masimo (MASI)$8.9B
Glaukos (GKOS)$7.8B
PROCEPT BioRobotics (PRCT)$5.1B
Integer Holdings (ITGR)$4.5B
Inari Medical (NARI)$3.1B
TransMedics (TMDX)$2.9B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.8B
Nihon Kohden (NHNKY)$2.5B
Tandem Diabetes Care (TNDM)$2.2B
Elekta AB (EKTAY)$2.2B
Integra LifeSciences Holdings (IART)$2.1B
RxSight (RXST)$2B
Alphatec Holdings (ATEC)$1.3B
Artivion (AORT)$1.2B